NHS, Red blood cell and CRISPR gene editing

‘Much-needed hope’ as CRISPR gene editing therapy recommended for sickle cell disease
Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant access to gene-editing therapy on the NHS. View on euronews
‘Ground-breaking’ gene treatment for sickle cell disease to be rolled out on NHS
A GROUNDBREAKING genetic treatment with the potential to cure sickle cell disease will be rolled out on the NHS. The one-off treatment costs more than £1million per patient but may essentially
Sickle cell disease ‘cure’ to be offered to NHS patients
Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem cell transplant
Gene-editing Therapy Could Be The Cure To Sickle Cell Disease
In 2019, the first CRISPR clinical trials were conducted to treat sickle cell diseases and in 2020, this treatment was injected directed into a human patient to treat hereditary blindness. The National Institute for Health and Care Excellence said it could suit around 50 patients per year.
Sickle cell disease: new treatment raises hopes of cure for sufferers
The Exa-cel gene therapy treatment is at the forefront of medical technology. It takes the person’s DNA and “edits” out the faulty sickle gene. It’s expensive, too. According to the manufacturer, Vertex, it costs £1.65 million per patient. But the NHS has negotiated a discount which is kept confidential.
NHS to offer 'groundbreaking' sickle cell gene therapy
The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts say.
Groundbreaking one-off gene therapy approved for severe sickle cell disease
People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE
NHS England to offer Casgevy for sickle cell disease patients
The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by approval for transfusion-dependent beta-thalassemia (TDT) in January 2024. NHS England reached an earlier reimbursement agreement for Casgevy in TDT in August 2024.
‘Functional cure’ for sickle cell disease now offered on NHS
Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell disease.
UK health system to offer cutting-edge gene therapy for sickle cell disease
Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the National Institute for Health and Care Excellence (NICE) said on Friday.
NHS to offer 'groundbreaking' sickle cell therapy as patients given 'very real prospect of cure'
A groundbreaking £1.65million gene therapy treatment offering hope for sickle cell disease patients has been approved for use on the NHS in England. The one-time treatment, called Casgevy (exa-cel), has shown remarkable success in clinical trials,
Sickle cell patients share delight over approval of new treatment
NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain ...
St. Louis American3h
Cardinal Glennon opens book club for kids with sickle cell disease
As is the case for institutions treating the disease, a majority of the sickle cell patients at SSM Health Cardinal Glennon Children’s Hospital are African American. The hospital recognized the need ...
STAT1d
Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease
People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...
MedPage Today1d
Biden Stacked Vaccine Committee; Sickle Cell and Sudden Death; NFL Concussions Down
The Pentagon ended a Biden-era policy that covered travel costs for servicemembers going out of state for abortion and other ...